持続 的 な 癌 細胞: 致命 的 な 生存 者
Shensi Shen1, Stéphan Vagner2, Caroline Robert3
1INSERM U981, Gustave Roussy Cancer Campus, Villejuif, France.
Cell
|November 13, 2020
まとめ
持続的な癌細胞は 治療に耐えられ 治療に失敗します 複雑な生存メカニズムを理解することで 癌治療の新たな標的となり 臨床前での成果が期待できます
科学分野:
- 腫瘍学
- 癌 生物学
- 細胞メカニズム
背景:
- 持続的な癌細胞は 治療を回避し 治療が失敗します
- これらの細胞は,緩やかな増殖,代謝の柔軟性,および表型の可塑性を示します.
- 生存には表遺伝的,転写的,転写的調節と 細胞の相互作用が含まれる.
研究 の 目的:
- 持続的な癌細胞生存のメカニズムを探求する.
- これらの細胞を排除するための 潜在的な治療標的を特定する
主な方法:
- 癌細胞生物学に関する最新の文献のレビュー
- エピジェネティック,トランスクリプション,およびトランスレーションの調節過程の分析.
- 癌の持続性における細胞間相互作用の調査
主要な成果:
- 持続的な癌細胞は 独特の適応生存戦略を持っています
- 多様な分子と細胞のメカニズムは その持続に寄与する.
- 臨床前試験では,これらの生存経路をターゲットにすることが有望であることが示されています.
結論:
- 癌の治療結果を改善するために 持続的な癌細胞をターゲットにすることが重要です
- 臨床的な翻訳には 複雑な生物学に関するさらなる研究が必要です
- これらの細胞に対する 治療法の開発は 重要な治療的可能性を秘めています
関連する概念動画
Cancer Stem Cells and Tumor Maintenance
5.5K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.5K
Adaptive Mechanisms in Cancer Cells
6.4K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.4K
Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Cancer
52.6K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
52.6K
Metastasis
6.1K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.1K
Cancers Originate from Somatic Mutations in a Single Cell
13.9K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
13.9K


